Amylyx Q2 FY26 net loss widens to $43.4 million; SG&A expenses climb to $21.9 million - AMLX News | RalliesAmylyx Q2 FY26 net loss widens to $43.4 million; SG&A expenses climb to $21.9 million
A
AMLX• Cash position and runway
- Cash, cash equivalents, and short-term investments slipped to USD 250.8 million.
- Cash runway is expected to fund operations into 2028.
Upcoming clinical catalyst
- The Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia is due to report topline data in late August or early September 2026.
Q2 results and expense trends
- Amylyx posted a Q2 net loss of USD 43.4 million, or USD 0.39 a share, versus a net loss of USD 41.4 million, or USD 0.46 a year earlier.
- R&D expenses fell 12.5% to USD 23.8 million, driven by lower spending on AMX0035 in progressive supranuclear palsy.
- SG&A expenses rose 40.4% to USD 21.9 million on higher legal costs and increased investment in commercial strategic initiatives.
